Why the Peptide Dosage Cheat Sheet You Screenshotted Might Be Wrong

You have probably seen it: a screenshot floating around forums and group chats, listing exact numbers for every peptide under the sun. "BPC-157: 250-500mcg twice daily." "Semaglutide: 0.25mg week 1, 0.5mg week 2." It looks like a settled recipe. It is not.

Not medical advice: This article discusses published research and general patterns, not a treatment plan for you specifically. Talk to a licensed healthcare provider before starting, stopping, or adjusting any peptide protocol.

Here's the uncomfortable part. The numbers on most of those cheat sheets were never tested for you. They were built from clinical trial averages, forum consensus, or a mix of both, and research keeps showing that the "right" dose swings wildly based on who's taking it. Let's look at why the chart you bookmarked might be doing you a disservice.

The Popular Belief: A Fixed Chart Should Work for Everyone

The logic feels sound. If a drug got tested in a clinical trial and a specific dose worked for most people, why not just follow that schedule? Semaglutide and tirzepatide both have FDA-approved titration schedules for exactly this reason, start low, go slow, land on a target dose. Research peptides like BPC-157 and TB-500 don't have FDA-approved doses, but online communities have converged on numbers that get repeated so often they start to feel official.

This isn't a crazy idea. Standardized starting doses exist because they reduce side effects and give doctors a predictable way to monitor patients. That's a real, evidence-backed reason to like a chart. But "predictable for the average trial participant" is not the same thing as "correct for you."

The Evidence That Complicates the Chart

Dose-finding trials exist because there is no single right number

Drug companies don't guess at one dose and call it done, they run phase 2 "dose-finding" trials specifically because response varies so much across a group. A 2026 phase 2 trial on the oral GLP-1/amylin drug zenagamtide tested multiple dose levels in adults with type 2 diabetes precisely because researchers needed to map out where benefits leveled off and side effects climbed [Source: PubMed, 42532079]. If drug makers with unlimited budgets and years of data still need a spread of doses to find what works, a single number on a screenshot is doing a lot of guessing on your behalf.

The same pattern shows up with oral orforglipron. A 2026 meta-analysis found its weight and blood sugar effects differed by a person's diabetes status, meaning the same milligram amount produced different real-world outcomes depending on the person's baseline metabolic health [Source: PubMed, 41640110]. A cheat sheet can't capture that kind of nuance; it just gives you the average.

Real-world results don't match trial results

This is the part that surprises people most. A 2026 real-world study comparing semaglutide and tirzepatide against bariatric surgery found that outcomes for people using these drugs outside of controlled trial settings looked meaningfully different from the outcomes reported in the original approval studies [Source: PubMed, 42345739]. Trials happen under tight supervision with selected participants. Real life has missed doses, food interactions, other medications, and totally different starting bodies. The chart was built for the lab, not for your kitchen counter.

Age, sex, and body size change how a dose behaves

Our own coverage of this exact issue found that GLP-1 drug response varies significantly by age, sex, and BMI, the same dose can produce very different weight loss and side effect profiles across these groups (see our breakdown on why GLP-1 treatment effects differ by age, sex, and BMI). A cheat sheet that lists one number for "adults" is flattening a variable that researchers now treat as central to predicting outcomes.

This lines up with broader research into why GLP-1 weight loss results vary so much between people even at identical doses. Genetics, gut hormone sensitivity, and baseline metabolic rate all factor in, none of which show up on a dosage chart.

Even the *outcome* of the same dose isn't fixed

A 2026 study on semaglutide found that up to 45% of the weight lost on the drug can come from muscle, not fat, but pairing the drug with ketone esters blunted that muscle loss significantly in the same dosing conditions [Source: PubMed, 42262870]. Same peptide, same dose, different result depending on what else is happening in the body. That's a hard thing to put on a static chart, because the chart assumes the dose is the only variable that matters.

Research peptide charts have even less behind them

Here's where it gets riskier. Semaglutide and tirzepatide at least have FDA-reviewed dose-finding data behind their titration schedules. Compounds like BPC-157 and TB-500 do not; there is no human dose-finding trial establishing "250mcg twice daily" as a validated number. Those figures largely trace back to animal studies scaled up by amateur math, or repeated anecdotal reports that calcified into consensus. If you're following a BPC-157 dosing guide or a TB-500 dosage chart, it's worth knowing the number is a starting reference point built on limited data, not a clinically validated dose the way an approved drug's titration schedule is.

The Best Argument for Keeping the Chart

To be fair to the cheat sheet, there's a real case for it. Standardized titration schedules for approved drugs like semaglutide and tirzepatide exist because slow, predictable dose increases measurably cut down on nausea, vomiting, and dropout rates in trials. That's not nothing, GI side effects are the number one reason people quit GLP-1 drugs early, and a structured schedule genuinely helps most people push through the first few weeks.

There's also a safety argument: without any starting reference point, people improvise, and improvising with injectable compounds is how overdosing and unpredictable reactions happen. A chart, even an imperfect one, gives a floor to start from and a shared language between patient and prescriber. The WHO's own review of global GLP-1 recommendations noted that inconsistent dosing guidance across countries has created real confusion and inequity in access to appropriate care [Source: PubMed, 42297706], which suggests the answer isn't "throw out the chart," it's "don't treat the chart as the finish line."

So the honest middle ground: an FDA-reviewed titration schedule is a reasonable, evidence-supported starting point. A crowdsourced research-peptide chart is a rough estimate at best. Neither should be treated as the final word on what your body needs.

What to Actually Do Instead of Trusting a Screenshot

If a fixed chart isn't the answer, what is? A few practical shifts:

Treat the standard schedule as a floor, not a finish line. For FDA-approved drugs, starting at the lowest labeled dose and titrating slowly is well-supported. Our tirzepatide dosing and titration guide walks through how that schedule is designed to be adjusted based on your own side effect response, not followed blindly to the target dose on a fixed calendar.

Track your own response, not the chart's assumptions. Nausea that isn't easing, blood sugar that's dropping faster than expected, or weight loss that's stalling are all signals that the "standard" number might not be your number. A peptide dosage calculator can help you understand how concentration and volume affect what you're actually injecting, which matters more than most people realize, since dosing errors from reconstitution mistakes are common and have nothing to do with the chart being right or wrong.

Be extra skeptical of precise-looking numbers for unapproved compounds. A number that looks specific ("250mcg") can create false confidence. For research peptides without human dose-finding trials, that precision is an illusion. Treat those numbers as a loose starting reference, not a clinical fact.

Loop in a provider who will actually adjust with you. The whole point of a titration schedule is that it's meant to be modified based on how you respond. A one-size-fits-all screenshot can't do that. A person watching your labs and symptoms can.

Where This Leaves You

The chart isn't a scam, and it isn't useless. For FDA-approved drugs, it's a reasonably evidence-backed starting point built from real trial data. For research peptides, it's closer to folklore, repeated so often it feels solid, without the human trials to back it up.

Either way, the research is fairly consistent on one point: the same dose does not produce the same result in different people, and sometimes not even in the same person over time. If you're using a cheat sheet as your only source of truth, you're borrowing an average that was never built with your specific body in mind.

---

Medical Disclaimer: The information on this website is for educational and informational purposes only. It is not intended as medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before starting any peptide protocol, medication, or supplement regimen. Individual results vary. This article shares published research and general patterns, not medical recommendations. Peptides such as BPC-157 and TB-500 are not FDA-approved for human use and are discussed here as research compounds only.

Sources

1. Efficacy and Safety of Oral GLP-1 RA Orforglipron on Weight and Glycemic Control According to Diabetes Status: A Systematic Review and Meta-Analysis, Diabetes Technology & Therapeutics, 2026
2. Efficacy and safety of once-daily oral zenagamtide, a novel unimolecular GLP-1 and amylin receptor agonist, in adults with type 2 diabetes: a phase 2 dose-finding trial, 2026
3. From obesity guideline to diabetes practice: WHO GLP-1 recommendations between promise, uncertainty and global inequity, Journal of Diabetes and its Complications, 2026
4. Real-World Effectiveness of Semaglutide and Tirzepatide Compared With Bariatric Surgery, 2026
5. Semaglutide-induced loss of skeletal muscle mass is blunted by co-administration of ketone esters, JCI Insight, 2026
6. Mazdutide and Orforglipron, New Evidence in Obesity and Diabetes, JAMA, 2026